|
Daily Medical Update
Pruritus
Monday, August 10, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
International journal of dermatology (2026) - Meta-Analysis
Key Findings
- Dupilumab reduced pruritus by MD -5.76 (95% CI -6.86 to -4.67) and improved quality of life by MD -11.84 (95% CI -22.76 to -0.92) in pooled prurigo nodularis data.
- Adverse events were reported in 13% of dupilumab-treated patients; phototherapy produced 23% complete and 60% partial responses, while thalidomide produced 15% complete and 49% partial responses.
📋 Practice Implication: For severe prurigo nodularis, the pooled results support prioritizing dupilumab when conventional options provide inadequate control, while reserving phototherapy or thalidomide for selected cases with careful safety review.
|
Acta dermato-venereologica (2025) - Practice Guideline
Key Findings
- The guideline summarizes population estimates of chronic pruritus in one in five people over a lifetime and a 7% 12-month incidence.
- The updated framework increases subtype-specific treatment options by incorporating newly approved on-label therapies for chronic prurigo and cholestatic pruritus.
📋 Practice Implication: Use the guideline to structure etiologic evaluation and stepwise multimodal care, matching newer on-label agents to the relevant pruritus subtype rather than treating itch as an isolated symptom.
|
Anais brasileiros de dermatologia (2025) - Meta-Analysis
Key Findings
- Nemolizumab reduced pruritus at week 4 versus placebo with a mean difference of -32.04 (95% CI -38.47 to -25.62) in pooled randomized-trial data.
- Investigator's Global Assessment success favored nemolizumab at week 16 (RR 3.50, 95% CI 2.18-5.63), with no significant difference in adverse or serious adverse events versus placebo.
📋 Practice Implication: Nemolizumab is a rapid IL-31-directed option for moderate-to-severe prurigo nodularis, with early itch benefit and no detected excess in adverse-event risk versus placebo.
|
Pediatric allergy and immunology (2026) - Meta-Analysis
Key Findings
- Ruxolitinib improved IGA treatment success at week 4 (RR 4.56, 95% CI 3.01-6.92) and week 8 (RR 4.00, 95% CI 2.97-5.38) versus vehicle.
- EASI75 response and at least 4-point pruritus-NRS improvement were significantly higher with ruxolitinib, while overall treatment-emergent adverse-event risk was similar to vehicle (RR 0.87, 95% CI 0.74-1.03).
📋 Practice Implication: Topical ruxolitinib offers a steroid-sparing option for atopic dermatitis when a topical anti-inflammatory is appropriate, with efficacy across ages and dosages and vehicle-like overall treatment-emergent adverse-event risk.
|
Alimentary pharmacology & therapeutics (2026) - Randomized Controlled Trial
Key Findings
- In patients with baseline NRS ≥4, seladelpar improved mean itch severity from the moderate to mild range, whereas placebo did not.
- Seladelpar reduced itch distribution and consistently improved itch-related sleep disturbance; fatigue measures also improved versus placebo in patients with severe baseline itch.
📋 Practice Implication: In primary biliary cholangitis with persistent itch despite or intolerance to ursodeoxycholic acid, seladelpar may address both itch severity and its sleep and fatigue consequences, extending benefit beyond an itch score alone.
|
|
💡
Summary
The first-pass pool contains more than five candidates at or above the requested clinical-significance threshold, so this payload selects the five highest-priority studies without invoking the sparse-pool caveat. The evidence emphasizes subtype-directed care: dupilumab and nemolizumab for prurigo nodularis, topical ruxolitinib for atopic dermatitis, seladelpar for cholestatic pruritus in primary biliary cholangitis, and guideline-based diagnostic and stepwise management.
|
|